Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

Headache, Migraine Clinical Trial

Official title:

Pharmacologic and Genetic Evaluation of a C. Elegans Model for Migraine

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01122381
• Other study ID #: B5043-R
• Status: Terminated
• Phase: Phase 1/Phase 2
• First received: May 10, 2010
• Last updated: August 11, 2015
• Start date: December 2011
• Est. completion date: April 2014

Study information

• Verified date: August 2015
• Source: VA Office of Research and Development
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal GovernmentUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether ethosuximide works better than placebo in the prevention of episodic migraine among veterans.

Description:

Chronic and episodic headaches in veteran populations include migraine, transformed migraine, and post-traumatic headache with migrainous features. More and better prophylactic drugs with fewer side effects (such as weight gain) are needed to treat these disabling, refractory conditions which generally have less than a 50% response rate to preventative treatments.

Rare forms of severe familial hemiplegic migraine (FHM) are considered channelopathies and can be caused by mutations in a calcium channel gene. Serotonin is also known to be a critical neurotransmitter in migraine based on the pharmacology of acute and preventative treatments. We previously identified a "migraine" signaling pathway in an invertebrate C. elegans "hemiplegic migraine" model of a mutant calcium channel upstream from transforming growth factor-beta (TGF-beta) and showed that low serotonin levels can be rescued by treatment with the childhood antiepileptic drug ethosuximide (ESX).

Objective: We propose to test our findings from this invertebrate migraine model to determine its relevance to humans in the prevention of episodic migraine.

Primary Aim: Determine whether ethosuximide (ESX) will be significantly more effective than placebo in reducing migraine headache days. We propose a 3 year, double blind, phase 1/2 randomized, 2:1 ESX:placebo controlled parallel trial in episodic migraineurs comparing migraine headache days during the last 4 weeks of treatment to a pre-treatment 4 week baseline.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: April 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Must be a veteran.

• The number of migraine days per 4-week period is to be 4-14 for a period of 3 months prior to screening for entry into the trial.

• Migraine must have been occurring for 6 months preceding entry into the trial and age of onset should be before age 60 years.

• Migraine must be at least moderate severity and interrupt daily activities in some respect at least 3 times per month.

• As long as the veteran can easily distinguish nonmigraine headaches from migraine, there is no limit on the number of non migraine headache days allowed. "Transformed migraine" headaches due to medication over usage will be excluded according to exclusion criteria #4.

• Migraine diagnosis:

Veterans with headache must have migraine categorized using the International Headache Society (I.H.S.) criteria as illustrated below for the two main types with and without aura.

Criteria for migraine without aura (I.H.S. 1.1)

• > 5 attacks

• headache lasting 4-72 hours when untreated or not successfully treated.

• headache with two of the following characteristics

• unilateral,

• pulsating,

• moderate to severe intensity,

• aggravation by exertion.

• one of the following occurs with headache

• nausea and/or vomiting

• photophobia and phonophobia

Criteria for migraine with aura (I.H.S. 1.2)

• at least 2 attacks

• at least three of the following characteristics:

• One or more fully reversible aura symptoms indicating focal cerebral cortical - and/or brain stem dysfunction.

One or more aura symptoms of the following types:

• Homonymous visual disturbance

• Unilateral parenthesis and/or numbness

• Unilateral weakness

• Aphasia or unclassifiable speech difficulty

• At least one aura symptom develops gradually over more than 4 minutes or, 2 or more symptoms occur in succession.

• No aura symptom lasts more than 60 minutes. If more than one aura symptom is present, accepted duration is proportionally increased.

• Headache follows aura with a free interval of less than 60 minutes. (It may also begin before or simultaneously with the aura). Headache, nausea and/or photophobia usually follow neurological aura symptoms directly or after a free interval of less than an hour. The headache usually lasts 4-72 hours, but may be completely absent (1.2.5, acephalgic migraine).

Exclusion Criteria:

• Veterans with migraine plus other systemic disorder will be excluded if migraine onset was temporally related to onset of the systemic disorder.

• Blood pressure elevations (must be < borderline values 135/85 for 4 weeks before enrollment into the study). Current treatment for hypertension with beta-blockers, calcium channel blockers, or ace inhibitors not allowed.

• Use of other prophylactic migraine drugs (requires a washout phase) and cannot have failed more than two other prophylactic drugs for migraine.

• Excessive use of acute pain medicines, including narcotics (>10 days month). Those using non-narcotics could be tapered off over 4-8 weeks.

• Receiving disability or seeking disability for headache or chronic pain.

• Significant neck pain or cervicogenic contributors to chronic headache.

• Significant depression, anxiety, post-traumatic stress disorder, or other disabling psychiatric condition.

• Known allergies or serious side effects with ESX or succinimides in the past.

• Known liver or significant renal disease.

• Women veterans of child-bearing age who do not have adequate birth control.

• Chronic bone marrow suppression.

• Using psychogenic or other sedating maintenance drugs.

• History of porphyria.

• History of cluster headache. 15.History of other CNS disease.

• Age younger than 18 years and greater than 65.

• Women veterans who are breastfeeding.

• Veterans with familial hemiplegic migraine (FHM).

Ongoing exclusions during the study:

• The addition of other migraine prophylactic headache medicines is not allowed. 2. New drugs cannot be added that aggravate headache (nitrates, dipyridamole, niacin).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Headache
• Headache, Migraine
• Migraine Disorders

Intervention

Drug:
• ethosuximide
ethosuximide (ESX)

Other:
• placebo comparator
placebo

Locations

Country	Name	City	State
United States	VA Pittsburgh Health Care System	Pittsburgh	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
VA Office of Research and Development	Thomas Jefferson University, University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Migraine Headache Days Per 4 Week Period Comparing the Last 4 Weeks of Treatment to a 4 Week Pre-treatment Baseline.	Compare number of migraine headache days pre and post treatment between the ESX and placebo group.; Study terminated early-no outcome data available. The single subject assigned to study drug did not actually take it according to subsequent review of ESX drug levels.	4 weeks, end of treatment and pre-treatment baseline	No